UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 5, 2007
Medicis Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-18443
|
|
52-1574808 |
| |
|
|
|
|
| (State of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification Number) |
8125 North Hayden Road
Scottsdale, Arizona 85258-2463
(Address of principal executive offices) (Zip Code)
(602) 808-8800
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01 Other Events.
On December 5, 2007 Medicis Pharmaceutical Corporation (“Medicis” or the “Company”) and Ipsen,
S.A. (”Ipsen”) issued a joint press release announcing the submission of the Biologics License
Application (“BLA”) for RELOXIN® with the U.S. Food and Drug Administration (“FDA”). Upon FDA’s
acceptance of the RELOXIN® submission, Medicis will pay Ipsen approximately $25 million in
accordance with the companies’ previously announced Development and Distribution Agreement (“DDA”).
Pursuant to the DDA, in March 2006, Ipsen Ltd., a wholly-owned subsidiary of Ipsen, granted
Aesthetica Ltd., a wholly-owned subsidiary of the Company, rights to develop, distribute and
commercialize Ipsen’s botulinum toxin product in the United States, Canada and Japan for aesthetic
use by physicians. A copy of the joint press release is furnished herewith as Exhibit 99.1 and is
incorporated by reference herein.
Item 9.01 Exhibits.
(c) Exhibits
99.1 Press Release dated December 5, 2007